UCB and Biogen Idec are partnering to develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis (MS) and other potential indications. CDP323 is an orally active small molecule alpha4-integrin inhibitor expected to enter Phase II trials next year.
Under terms of the agreement, UCB will receive upfront and additional payments for development and commercial milestones in excess of $200 million. Furthermore Biogen Idec will contribute significantly to clinical costs for Phase II and Phase III studies. All commercialization costs and profits will be shared equally.
“We are always looking to enhance and expand our arsenal in the fight against MS,” said Al Sandrock, senior vp, neurology research and development for Biogen Idec. “Another effective oral therapy would augment Biogen Idec’s broad portfolio of products and potential therapies in development for this debilitating disease.”